Analysis of the metabolism of haloperidol (HP) and its neurotoxic pyridinium metabolite (HPP+) in patients with drug-induced parkinsonism.
Iwahashi
K
K
Anemo
K
K
Nakamura
K
K
Yoshihara
E
E
Igarashi
K
K
D000328:Adult; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D005260:Female; D006220:Haloperidol / Q000031:analogs & derivatives* / Q000097:blood*; D006801:Humans; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000097:blood* / Q000139:chemically induced*; D011726:Pyridinium Compounds / Q000097:blood*
D011726:Pyridinium Compounds; C085216:N-(4'-fluorobutyrophenone)-4-(4-chlorophenyl)pyridinium; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D019389:Cytochrome P-450 CYP2D6; D051544:Cytochrome P-450 CYP3A; D006220:Haloperidol